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Abstract
Monitoring for drug-induced liver injury (DILI) via serial transaminase measurements in patients on potentially hepatotoxic
medications (e.g., for HIV and tuberculosis) is routine in resource-rich nations, but often unavailable in resource-limited
settings. Towards enabling universal access to affordable point-of-care (POC) screening for DILI, we have performed the first
field evaluation of a paper-based, microfluidic fingerstick test for rapid, semi-quantitative, visual measurement of blood
alanine aminotransferase (ALT). Our objectives were to assess operational feasibility, inter-operator variability, lot variability,
device failure rate, and accuracy, to inform device modification for further field testing. The paper-based ALT test was
performed at POC on fingerstick samples from 600 outpatients receiving HIV treatment in Vietnam. Results, read
independently by two clinic nurses, were compared with gold-standard automated (Roche Cobas) results from
venipuncture samples obtained in parallel. Two device lots were used sequentially. We demonstrated high inter-operator
agreement, with 96.3% (95% C.I., 94.3–97.7%) agreement in placing visual results into clinically-defined ‘‘bins’’ (,3x, 3–5x,
and .5x upper limit of normal), .90% agreement in validity determination, and intraclass correlation coefficient of 0.89
(95% C.I., 0.87–0.91). Lot variability was observed in % invalids due to hemolysis (21.1% for Lot 1, 1.6% for Lot 2) and
correlated with lots of incorporated plasma separation membranes. Invalid rates ,1% were observed for all other device
controls. Overall bin placement accuracy for the two readers was 84% (84.3%/83.6%). Our findings of extremely high inter-
operator agreement for visual reading–obtained in a target clinical environment, as performed by local practitioners–
indicate that the device operation and reading process is feasible and reproducible. Bin placement accuracy and lot-to-lot
variability data identified specific targets for device optimization and material quality control. This is the first field study
performed with a patterned paper-based microfluidic device and opens the door to development of similar assays for other
important analytes.
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Introduction
There is great need for high-quality, low-cost, point-of-care
(POC) diagnostics that can increase access to testing and improve
patient care in resource-limited settings. An important example of
inadequate access to testing in resource-limited settings is
monitoring for drug-induced liver injury (DILI) in patients on
potentially hepatotoxic medications. In resource-rich settings,
serial monitoring for DILI via measurements of serum transam-
inases (aspartate aminotransferase [AST] and alanine aminotrans-
ferase [ALT]) in at-risk patients (particularly those with underlying
liver disease) is a standard part of medical care. However, this
monitoring is often limited or unavailable in resource-limited
settings. Monitoring for DILI is particularly relevant for patients
on tuberculosis (TB) and/or HIV therapy [1,2], and thus lack of
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e75616access to this testing is particularly problematic in the resource-
limited areas most affected by these diseases. Transaminase
monitoring typically involves collecting whole blood by venipunc-
ture, centrifuging to separate serum or plasma, and testing that
serum/plasma on a large automated platform. Such systems
require highly trained technicians for maintenance and are quite
expensive, impacting test availability in resource-limited settings. If
performed, testing is often done in centralized or regional
laboratories, lengthening result turn-around times. Because of
these obstacles, in many resource-limited settings patients on
potentially hepatotoxic medications receive minimal or no
monitoring during treatment.
To advance towards the ultimate goal of providing universal
access to affordable POC DILI screening, Pollock and Rolland
et al. have recently described development and early clinical
testing of a paper-based, multiplexed, microfluidic assay designed
for rapid, semi-quantitative, and visual measurement of AST and
ALT in a fingerstick specimen [3]. This device is a representative
of an emerging class of paper-based microfluidic platforms [4–20].
There is currently great interest in the potential diagnostic utility
of microfluidic platforms based on paper, given the benefits of
portability, disposability, lack of power and instrumentation
requirements, and extremely low cost. Paper-based microfluidic
devices consist of hydrophilic paper channels defined by pattern-
ing of hydrophobic barriers (e.g., [3,4,6,7,18,20]) or by cutting
(e.g., [10–14,17]). Using these defined channels, fluid flow (drawn
by wicking) can be directed towards specific detection zones and
operations such as filtration, mixing, and splitting can be
performed autonomously. Proof-of-principle studies [5–18,20]
have demonstrated the ability to conduct clinical chemistry,
enzymatic, and immunoassay tests on patterned paper, visually
and quantitatively (the latter through the use of cell phone
cameras), and thus have demonstrated the potential for clinical
application of paper-based microfluidic technology. The work by
Pollock and Rolland et al. [3] advanced this field by presenting the
first validation of a paper-based microfluidic device using real
clinical specimens and the first demonstration of a field-ready
prototype clinical test for transaminase monitoring. That study
showed that the paper-based assay could, in 15 minutes, provide
visual measurements of AST and ALT in whole blood or serum
which allowed the user to place those values into one of three
readout ‘‘bins’’ (,3x upper limit of normal [ULN], 3–5x ULN,
and .5x ULN, corresponding to familiar clinical thresholds for
TB and HIV treatment monitoring, e.g. [1,2]) with .90%
accuracy as compared to automated methods [3].
Despite this large body of proof-of-principle work in the field of
paper-based microfluidics, there has yet to be an actual field study
showing that a clinical diagnostic assay utilizing this platform
technology actually works for real-time clinical testing in a target
clinical population and setting. Note that we distinguish paper-
based microfluidic tests from lateral flow tests, which are widely
used in current clinical practice (including at POC). Lateral flow
tests are also considered ‘‘paper-based devices’’ in that they utilize
absorptive material strips. However, they typically are limited to
immunoassays and run small numbers of tests (1 to 2) in series
(requiring that reagents and buffers for each test be compatible
and that assays not cross-react). In contrast, paper-based
microfluidic devices, similarly to their conventional plastic-based
microfluidic counterparts, can be designed to integrate many
analytical functions and perform assays based on a wide range of
assay principles [19,21]. As discussed in this paper, they can also
split a single, low-volume (,40 ml) sample into multiple separate
streams, each of which can be assayed in parallel. This avoids
cross-reactivity between assays and allows for high-level multi-
plexing of independently optimized assays.
We here present the results of the first fingerstick evaluation of
an ALT-only version of the paper-based transaminase test in 600
patients undergoing HIV treatment in a single clinic in Vietnam.
The goals of this study were to assess operational feasibility, inter-
operator variability, lot-to-lot variability, device failure rate, and
device accuracy, with the intention to utilize results to modify the
device for further field testing as needed. Our results, obtained in a
target clinical population and environment, as performed by local
health care workers, indicate that the device operation and reading
process is both feasible and reproducible, thus answering a major
question about the potential usability of this type of device. Bin
placement accuracy data and lot-to-lot variability analysis
identified specific targets for device optimization and material
quality control.
Materials and Methods
Device Production
Devices were fabricated as previously reported [3] and pouched
individually in foil-lined bags with one (1 gm) packet of silica
(Electron Microscopy Sciences, Hatfield, PA) per bag. Two device
lots (LFT042412 and LFT061312) were produced and used for
this study. These devices had a shelf-life of five months if stored at
35uC, as estimated from accelerated stability data.
Device Shipment and Storage
Each of the two device lots was shipped (via FedEx) from Boston
to Ho Chi Minh City and stored at ambient temperatures, to
approximate the probable conditions of distribution of a
commercially available device. Temperatures during shipment
were recorded for Lot 2 using a temperature monitor (TinyTag
Talk 2 Temp Logger TK-4014), and the resulting profile used as a
proxy for the Lot 1 shipment (which did not include a data logger).
Ambient temperatures during study enrollment were monitored
using a temperature and humidity data logger (ExtechH) set to
record at 15-minute intervals. Historical temperature data (daily
minimum, maximum, and mean) from Weather Underground
(wunderground.com) was used as a proxy for ambient tempera-
tures in the clinic during periods when no data logger data was
available (between pilot and study start, and over two weekends at
the start of enrollment). A comparison of five daily measurements
(minimum, maximum, mean) from the clinic data logger and
Weather Underground confirmed agreement of the two sources of
temperature data.
Study Setting and Population
Subjects were recruited from the outpatient HIV clinic of the
Hospital for Tropical Diseases (HTD), Ho Chi Minh City,
Vietnam. Eligible patients were adults ($18 years old) receiving
HIV treatment through the HTD clinic who were scheduled to
receive routine ALT monitoring on the day of enrollment, willing
to undergo a fingerstick in addition to routine care, and able to
provide informed consent.
Study Training Procedures
Training was conducted in conjunction with preparation for the
pilot study, approximately one month prior to study start, with
proficiency tests immediately before the start of both the pilot and
evaluation studies. Training was tailored for the purposes of this
study and was provided by representatives of the sponsor (PATH)
and the device manufacturer (Diagnostics For All [DFA]), who
offered intensive, individualized instruction to each nurse. The
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recruitment procedures, overview of the device structure and
function, steps for completing the fingerstick and transferring
sample to the device per the manufacturer’s product insert, and
practice reading with mock devices (with various specific ALT
values and control results represented in the detection zones,
generated using scanned images of completed devices). In
addition, nurses were specifically instructed about the study
requirement to read and record device results privately, without
interaction with any other individual. The study nurses were
required to pass a proficiency test using the mock devices (pass
criteria: $80% bin placement accuracy and 100% determination
of invalids) before patient enrollment could start. If they failed this
test, they were retrained with the mock devices and given another
test. Each nurse was allowed a maximum of two trials to pass the
test. During the pilot phase (see below), the study nurses received
immediate feedback on correct and incorrect use (including
fingerstick, sample transfer procedure, and device reading) from
an expert user (DFA representative). No additional training or
feedback was given once evaluation study enrollment began.
Study Protocol
All tests were performed as per a product insert provided by the
manufacturer (DFA, Cambridge, MA, USA). After wiping fingers
with alcohol swabs, fingersticks were performed with safety lancets
(SurgiLanceH SLN 300, MediPurpose, Duluth, GA, USA) and
blood collected with commercially available 35-mL capillary tubes
(Microsafe, SafeTec LLC, Ivyland, PA, USA). Devices were
incubated for 12 to 14 minutes as per the product insert (time
dependent on ambient temperature) in open petri dishes in a
separate incubation area for safety. These petri dishes were
cleaned daily with a bleach solution and replaced weekly.
Following the allocated incubation period, each device was read
in quick succession by two nurses, defined by role as N1 (who
conducted the fingerstick and sample transfer to the device) and
N2 (who set the timer for the incubation period and moved the
petri dish to the device incubation area.) (Note: the N1 role was
filled by one of the three trained study nurses for the entire study;
the other two study nurses took turns filling the N2 role). N2
typically (but not always) read the device first, followed by N1, who
had the more time-consuming task of performing the fingersticks
and managing patient flow. The nurses were specifically instructed
not to communicate during the reading procedure and adhered to
this procedure, preserving the independence of the two readings.
Each device was scanned immediately after visual reading (Canon
Inkjet Photo All-in-One PIXMA MP287, Canon Inc., Tokyo,
Japan). Neither the patients nor their doctors were informed of the
results of their fingerstick testing.
Automated ALT testing was performed in parallel (Roche
CobasH ALT assay without pyridoxal phosphate activation, run on
a Roche CobasH 6000 platform with C311 and C501 analyzer
modules) using blood obtained by venipuncture (venipuncture was
performed prior to fingerstick). Per clinic and laboratory routine,
blood was sent to the HTD clinical laboratory within one to two
hours after draw and separated by centrifugation to generate
plasma for AST/ALT testing on the Roche CobasH platform per
the manufacturer’s protocol (Roche Diagnostics, Indianapolis, IN,
USA). Specimens went on the machine for testing within 30
minutes of receipt in the laboratory. Results obtained using this
method are in U/L, with normal reference ranges of 0 to 40 U/L
(male) and 0 to 33 U/L (female).
Additional clinical and laboratory data was collected as
available for each subject, including hepatitis B virus (HBV)
status, hepatitis C virus (HCV) status, current HIV medications,
current TB medications (if any), and most recent CD4 count/date.
Results of any laboratory tests ordered concurrently with ALT on
the day of enrollment were also captured as available (specifically
including AST, hemoglobin, hematocrit, platelet count, creatinine,
and CD4).
A pilot study (50 subjects) was performed first to assess
operational feasibility of the device and to confirm that the study
procedures were working as expected in the clinic environment.
Following the pilot, enrollment for the evaluation study (600
subjects) commenced. Data from the pilot study was not combined
with data from the evaluation study, and data from the pilot study
is not reported in this manuscript. The sample size for the
evaluation study was driven by numbers of subjects needed to
enroll in order to ultimately obtain at least 20 fingerstick tests from
subjects with gold-standard ALT values falling in the upper bin
(.5x ULN).
Human Subjects Protections/Ethics Statement
This study was approved by the PATH Research Ethics
Committee and by the respective Institutional Review Boards of
the Hospital for Tropical Diseases and Beth Israel Deaconess
Medical Center. All subjects provided written informed consent.
Statistical Analysis
All data analysis was conducted using R (http://www.R-project.
org). Binary results were compared using proportions with exact
confidence intervals, and inter-reader agreement was assessed
using the joint probability of agreement, diagonal plots, and the
intraclass correlation coefficient (ICC).
Results
3-zone Paper-based Transaminase Test: Design,
Production, and Storage
DFA’s postage-stamp-sized (3362060.5 mm), 3D device is
made by layering patterned paper (Figure 1A). To create each
layer of patterned paper, a wax-based printer and a heat source
are used to print hydrophobic barriers into a sheet of paper in
order to create microfluidic, hydrophilic paths within the paper,
through which flow (drawn by wicking) can be directed to specific
‘‘detection zones’’. Layers of patterned paper can be stacked to
generate 3D devices by depositing patterned layers of hydrophobic
adhesive via screen printing and adhering multiple sheets together.
This three-zone device enables performance of three measure-
ments on a single fingerstick sample: one zone measures ALT and
two control zones ensure proper device performance (Figure 1A).
Each of the three zones has a unique environment (reagents,
buffers, pH) that ensures specificity. Fingerstick blood is collected
using a lancet and capillary tube (Methods) and applied directly to
the device (Figure 1B). The ALT assay, based on peroxidase
chemistry ([3]; of note, the assay does not include pyridoxal
phosphate activation), generates a red dye in the presence of
elevated ALT levels. The test was carefully engineered for visual
readout, such that the ALT test zones provide a strong color
change across the target clinical range (Fig. 1C). The color change
was optimized to correspond to the cutoffs currently used for
clinical management decisions per TB treatment guidelines in the
United States [1]. Thus the results of the test are visually
interpreted as being within one of the following three ‘‘bins’’: ,3x
the ULN (0–119 U/L), 3–5x ULN (120–200 U/L), or .5x ULN
(.200 U/L). Using the additional color gradation within each bin
on the read guide, the reader can approximate where within the
bin the result falls, allowing semi-quantitative readout (Figure 1C).
The control zones notify the user of insufficient sample volume or
Field Evaluation of a Paper POC Transaminase Test
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75616Figure 1. Schematic of 3-zone paper-based transaminase test design and performance. (A) The paper-based transaminase test is made
from two layers of similarly patterned-paper, a plasma separation membrane (PSM), and lamination to protect the device from the environment. (A
and B) A hole in the lamination allows for a fingerstick blood sample (collected using a capillary tube) to be applied to the PSM; blood cells are
captured and retained by the PSM while plasma wicks into the individual ‘‘zones’’ in the first layer of paper below. In those zones, the plasma fluid
reconstitutes dried reagents (as required for the zone-specific chemistry) and continues to wick to the second layer of paper, where analytes in the
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reagents (viewed in the positive control zone); each zone is
interpreted as ‘‘valid’’ or ‘‘invalid’’ and an ‘‘invalid’’ result in any
control zone invalidates the entire device (Figure 1D).
Devices were produced at DFA (Cambridge, MA, USA) and
shipped to Ho Chi Minh City, Vietnam, where they were stored at
ambient temperature (Methods), primarily in the study clinic. Two
lots of devices were manufactured and were used sequentially for
the study (Lot 1 for the first 218 subjects; Lot 2 for the next 382
subjects). Each lot of devices spent approximately eight weeks in
storage in ambient conditions and all devices were used at least
eight weeks before expiration dates (based on storage at 35uC)
provided by the manufacturer. Daily temperatures in Ho Chi
Minh City (uC, Methods) during storage of each lot prior to use in
the study ranged from a minimum of 22–27 (average: 24.3) to a
maximum of 30–36 (average: 33.5) for Lot 1 devices and from a
minimum of 23–26 (average: 23.7) to a maximum of 31–34
(average: 33.1) for Lot 2 devices. Temperature ranges (uC)
measured in the clinic during study testing (via a temperature
logger) were 27.8–32.5 (average: 30.3) for Lot 1 and 28.3–32.7
(average: 29.9) for Lot 2. Comparison of maximum ambient city
temperatures to maximum temperatures measured in the clinic on
study testing days indicated that maximum city temperatures did
not underestimate the temperature maximums the devices
experienced in the clinic. Humidity ranges during study testing
(%) were 55.9–85.2 (average: 70.9) for Lot 1 and 54.4–83.3
(average: 72.7) for Lot 2.
Setting and Study Participants
The study was performed in the outpatient HIV clinic of the
Hospital for Tropical Diseases (HTD) in Ho Chi Minh City,
Vietnam. This clinic has approximately 3,000 HIV-positive
patients on treatment provided free through the Vietnam Ministry
of Health. A significant proportion are on Nevirapine-containing
regimens (known to confer risk of DILI) and co-infection with
HBV (15% prevalence) and/or HCV (25% prevalence) is common
(unpublished data, HTD). The clinic also has an existing practice
of routine transaminase monitoring (once every six months) for
patients receiving HIV treatment, following Vietnamese national
guidelines [22]. Eligible subjects (Methods) were recruited by their
physicians during routine clinic visits. To ensure enrollment of
sufficient subjects with ALT values ultimately falling into the
highest two bins (3–5x ULN and .5x ULN), patients with known
HBV, known HCV, or history of past elevated transaminases
($90 U/L) were prioritized for enrollment. Only patients
scheduled for routine clinical ALT testing (specimen collected by
venipuncture) by their physicians were recruited to the study; after
venipuncture, subjects proceeded to fingerstick collection.
All participants were ambulatory, enrolled in the free public
anti-retroviral therapy (ART) program at the hospital, and on
HIV treatment at the time of enrollment. The median age was 32
years (range 20 to 62) and 83% were male. Median CD4 count
(most recent measurement) was 277.5 cells/mm
3 (inter-quartile
range 199–397). Almost all subjects were on first-line ART; the
most common regimens taken were zidovudine/lamivudine/
nevirapine (32%), zidovudine/lamivudine/efavirenz (27%), and
tenofovir/lamivudine/efavirenz (18%). Only 3% of subjects were
on second-line ART containing lopinavir/ritonavir.
Pre-study Training
Training was intensive and individually tailored, as detailed
above (Methods); complete operational data collected during this
training will be reported separately. Training was conducted prior
to the 50-subject pilot phase, and nurses were required to pass a
proficiency test prior to beginning that pilot phase and a second
test prior to start of evaluation phase enrollment. Despite passing
the proficiency test prior to the pilot, expert observers determined
that the nurses required (and thus were given) additional guidance
during the pilot to correctly execute the sample transfer procedure
and later interpret the device readout, indicating that mock device
use during training was potentially insufficient without real-time
feedback during actual patient testing. By the completion of the
pilot, expert monitors observed that all three study nurses were
comfortable and proficient with both sample transfer and device
interpretation. The pre-evaluation phase proficiency test and a
study monitoring visit during the evaluation phase confirmed skills
retention.
Testing Protocol and Adherence
After completion of the 50-subject pilot study (Methods), the
paper-based ALT test was performed at POC on fingerstick blood
samples from 600 patients using a product insert provided by the
manufacturer, a safety lancet, and a 35-mL capillary tube
(Methods, Figure 1). A timer was set for an allotted device
incubation time as determined by the ambient temperature (20–
24uC, incubate 18 minutes; 25–29uC, 14 minutes; 30–33uC, 12
minutes; 34–37uC, 10 minutes; per the product insert, reading the
device within a 10 minute window after this incubation time was
acceptable.). When the timer went off (‘‘set time’’), the device was
read independently by each of two clinic nurses in turn, using the
read guide provided (Figure 1C); nurses were asked to indepen-
dently record both a result ‘‘bin’’ (,3x, 3–5x, or .5x ULN) and
an absolute value (U/L, rounded to the nearest 10 U/L) for ALT
results. Nurses also evaluated the two control spots to determine
whether the test was valid or invalid, following the product insert
(Methods, Figure 1D). The two nurses did not communicate with
each other during their reading. Temperature and humidity at the
time of testing were recorded as noted above. After completion of
visual reading, each device was digitally scanned (Methods) to
preserve data for subsequent expert interpretation (described
below).
All 600 testing events generated visually interpretable data.
There were no mismatches between measured ambient temper-
ature (via the clinic logger) and the setting of the timer as per the
guidelines in the product insert. The majority of devices were read
within 2 minutes of the set time by both nurses, and all devices
were read well within the 10-minute window allowed per the
product insert. For Nurse 1, only 45/600 devices were read more
than two minutes after the set time (32/45 were read three minutes
after, 9/45 were read four minutes after, 1/45 was read five
plasma react with additional dried reagents in each detection zone and generate visual colorimetric signals. (B and C) After a total of approximately
12 to 14 minutes incubation at ambient temperature, the color in the ALT test zone can be interpreted and semi-quantified using a visual ‘‘read
guide’’ (C). The results of the test are interpreted as being within one of the following three ‘‘bins’’: ,3x the upper limit of normal (ULN) (0–119 U/L),
3–5x ULN (120–200 U/L), or .5x ULN (.200 U/L). (D) 2 additional control zones notify the user of invalid results. The negative control zone (marked
‘‘2’’) allows assessment of insufficient sample volume (i, ii, zone white rather than yellow) or hemolysis (iv, zone red rather than yellow), while the
positive control zone (marked ‘‘+’’) allows assessment of damaged reagents (iii, zone not red); each zone is interpreted as ‘‘valid’’ or ‘‘invalid’’. A result
of ‘‘invalid’’ in either of the two control zones invalidates the entire device. (ALT=alanine aminotransferase. ULN=upper limit of normal).
doi:10.1371/journal.pone.0075616.g001
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and for Nurse 2, 13/600 devices were read greater than two
minutes after the set time (9/13 were read three minutes after, 3/
13 were read four minutes after, and 1/13 was read six minutes
after the set time).
Device Performance
Validity analysis. Two ‘‘expert readers’’ (one from PATH,
and one from DFA, both blinded to results of the nurses’ visual
reads) independently reviewed the scanned images to determine
whether each device was valid or invalid and, if invalid, why
(negative control failure, positive control failure, or failure of both
controls [Figure 1D]). All 600 scanned images were interpretable.
However, two devices and all associated data had to be excluded
from analysis due to enrollment error (one subject was not
currently taking HIV medications and thus did not meet inclusion
criteria, and the other was accidentally enrolled twice), leaving 598
device results available for analysis (218 from Lot 1, and 380 from
Lot 2.) 13/598 device results were read discordantly by the two
expert readers (11/13 were called invalid by only Expert Reader 1,
and 2/13 were called invalid by only Expert Reader 2). Notably,
the majority of this discordance was due to disagreement about the
presence or absence of visible hemolysis in the negative control
zone (Figure 1D, iv). To resolve this discordance, a third expert
reader (from DFA; also blinded to all other study results) was asked
to read a set of images including the discordant ones. The result
(valid or invalid) agreed upon by two of the three expert readers
was used as the final classification for each device.
After resolution of these discordant results, there were a total of
57 devices classified as invalid and 541 devices classified as valid
(overall invalid rate: 57/598 [9.5%]); these validity classifications
were subsequently used as the gold standard against which to
compare validity results obtained by the nurses reading the devices
in real time. Of these 57 invalid results, 52/57 were due to
negative control ‘‘failure’’ (specifically, hemolysis visible in the
negative control well; Figure 1D, iv), leading to an overall rate of
invalids due to hemolysis of 8.7% (52/598). Of these 52 devices
that were invalid due to hemolysis, 46 were devices from Lot 1
(46/218=21.1% hemolysis rate) and 6 were devices from Lot 2
(6/380=1.6% hemolysis rate). Review of materials used in the two
device lots revealed that different lots of plasma separation
membranes had been used to make the two device lots, suggesting
that this material was the basis of the substantial lot-to-lot
variability in hemolysis rates. 4/57 invalids were due to positive
control failure (see Figure 1D, iii; overall rate 0.7% [4/598]) and
1/57 invalids were due to negative control failure (i.e., failure to
‘‘activate’’ due to insufficient sample volume, Figure 1D, i and ii;
overall rate 0.2% [1/598]). There were no devices for which more
than one control zone ‘‘failed’’.
Gold-standard validity classifications were compared to the
classifications made by Nurse 1 and Nurse 2 (n=598 for Nurse 1,
and n=597 for Nurse 2 (Nurse 2 did not score validity for one
device)). Nurse 1 validity classifications showed 93.3% (91.0–95.2)
agreement with gold standard classifications, and Nurse 2 results
showed 90.6% (88.0–92.8) agreement with gold-standard classifi-
cations. The majority of the disagreement with the gold standard
for both nurses was due to a gold-standard ‘‘invalid’’ classification
versus a ‘‘valid’’ classification made by the nurse, and specifically
due to disagreement about the presence or absence of visible
hemolysis, suggesting that the expert readers (in review of the
scanned images) were seeing hemolysis that the nurses did not see
in real time. Nonetheless Nurse 1 and Nurse 2, both reading in
real time, agreed with each other on 571/597 classifications
(95.6% [93.7–97.1]).
Device accuracy. All 57 devices with gold-standard invalid
classification were excluded from further analysis, leaving 541
devices and associated data for analysis of device accuracy.
Additionally, 6/598 devices were excluded from analysis because
automated ALT testing of venipuncture blood had not been
performed (due to clerical error), leaving no automated result to
compare to the paper-based test. After these exclusions, there were
535 paper device and automated ALT result pairs available for
analysis. Our primary measure was bin placement accuracy, which
was defined as a visual device result which fell in the same ‘‘bin’’
(,3x ULN [,120 U/L], 3–5x ULN [120–200 U/L], or .5x
ULN [.200 U/L]) as the automated result. In a small number of
cases, a nurse assigned the wrong bin to a visual result (e.g., a result
of 200 U/L had been assigned to Bin 3 rather than Bin 2); these
mismatches were corrected prior to data analysis. The bin
distribution of true ALT values was as follows: 475 results fell in
Bin 1, 38 results in Bin 2, and 22 results in Bin 3 (total 535).
Results of bin placement analysis are shown in Figure 2A. Per-bin
accuracy was highest in Bin 1 (88.0/86.3% for Nurse 1 and Nurse
2, respectively) and lower in Bin 2 (65.8/76.3%) and Bin 3 (36.4/
36.4%). Overall bin placement accuracy for Nurse 1 was 84.3%
(80.9–87.3) and for Nurse 2 was 83.6% (80.1–86.6). A direct
comparison of Nurse visual-read ALT results (reported during
reading to the nearest 10 U/L) to true (automated) results (U/L) is
shown in Figure 2B. There were three devices for which visual-
read results (from both nurses) fell in Bin 1, but true results were in
Bin 3 (we refer to these as ‘‘major errors,’’ given that this would
mean that clinically significant hepatotoxicity [.200 U/L] would
have been missed) (Figure 2B). All three of these devices were from
Lot 1. Other than this finding, there were no other notable
differences in accuracy between the two device lots. Reanalysis of
the bin placement results (Figure 2C) using a binary cutoff
(,120 U/L=low, $120 U/L=high), as might be used in a
‘‘triage’’ or ‘‘screening’’ use scenario, generated bin placement
accuracies of 88.0/86.3% for the ‘‘low’’ bin for Nurse 1 and Nurse
2, respectively, and 73.3/80.0% for the ‘‘high’’ bin.
Inter-reader agreement. Nurse 1 and Nurse 2 agreed with
each other regarding bin placement for 96.3% (95% C.I., 94.3–
97.7) of device results. This high level of agreement between two
readers evaluating the same device in real time is graphically
represented in Figure 3, which plots the ALT result (to the nearest
10 U/L) read by Nurse 1 against the ALT result read by Nurse 2
for each device (of note, the high level of agreement between
Nurse 1 and Nurse 2 visual ALT reads is also evident when
comparing the two plots in Figure 2B). An intraclass correlation
coefficient of 0.89 (95% CI: 0.87–0.91) also indicated high
consistency for semi-continuous results (U/L). As noted above,
Nurse 1 and Nurse 2 also agreed with each other on 95.6% of
device validity classifications.
Discussion
Paper-based microfluidic devices offer the potential to meet the
need for low-cost, high-quality diagnostics that can improve
patient care in resource-limited settings. This study is the first-ever
field study performed with a patterned paper-based microfluidic
device and, we believe, establishes this paper-based transaminase
test as the most advanced representative of this emerging class of
devices. Our findings of extremely high inter-operator agreement
for visual reading–obtained in a target clinical population and
environment, as performed by local health care workers–indicate
that the device operation and reading process is both feasible and
reproducible, thus answering a major question about the potential
usability of this type of device. Bin placement accuracy data and
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device optimization and material quality control, and experiments
to address both aspects are currently in progress in preparation for
further field testing.
Successful development of this device for clinical use will require
further iterative device optimization, thorough exploration of
manufacturing conditions, device stability, and material quality
control, and further field testing under varied environmental
conditions. The intensive training allowed in the context of this
first field study is unlikely to be feasible or reproducible outside of
study contexts. A thorough understanding of the minimal training
requirements for novice users will ultimately be key to under-
standing the range of clinical environments in which this test can
be used–whether that be in centralized clinics as performed by
Figure 2. Comparison of paper-based transaminase test results to automated test results. (A) Bin placement accuracy. Nurse 1 (left table)
and Nurse 2 (right table) visual device results (classified by ‘‘bin,’’ i.e. Bin 1=,3x ULN [0–119 U/L], Bin 2=3–5x ULN [120–200 U/L], and Bin 3=.5x
ULN [.200 U/L]) were compared with automated device results (ALT Lab, also classified by bin) as the gold standard. Colored boxes indicate result
pairs in which the visual result was in the same bin as the automated result (green, ‘‘correct’’), a higher bin than the automated result (yellow,
‘‘overcall’’), or a lower bin than the automated result (red, ‘‘undercall’’). Per-bin accuracy for visual reading (Results) was calculated by dividing the
number of correctly binned samples in each bin by the total number of samples in that bin. Overall bin placement accuracy (Results) was defined as
the overall percentage of visual device results which fell in the same bin as the paired automated result. (B) Direct comparison of Nurse 1 (left plot,
ALTN1) and Nurse 2 (right plot, ALTN2) visual device results to automated test results (ALTLab) for each subject. In each plot, the black diagonal line
corresponds to the line of equality; the green diagonal lines correspond to +/240 U/L from the line of equality; and the blue boxes represent ALT
bins within which values for both the paper-based device and the automated method are within the same range: ,3x ULN (0–119 U/L), 3 to 5x ULN
(120–200 U/L), or .5x ULN (.200 U/L). (C) Reanalysis of the bin placement results (Nurse 1, left table; Nurse 2, right table) using a binary cutoff
creating only two bins (,120 U/L=low, $120 U/L=high), as might be used in a ‘‘triage’’ or ‘‘screening’’ use scenario. (ALT=alanine
aminotransferase. ULN=upper limit of normal).
doi:10.1371/journal.pone.0075616.g002
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minimally trained health-care workers, or even at home as
performed by patients themselves.
Our study does have some limitations which should be noted
here. First, while the clinic nurses were not told anything about
prior ALT data for any subject, it is possible that they may have
known some of the patients from prior clinic visits and may have
had some recollection of their baseline ALT status. Second,
because our protocol was designed to have no impact on routine
clinical care, secondary laboratory data were only available when
they were included as part of routine patient care. We were
therefore unable to obtain comprehensive data for HCV or HBV
status (as many patients had not had prior testing), or for other lab
tests done concurrently with ALT, such as hematocrit, hemoglo-
bin, platelet count, or creatinine (as many patients did not have
these tests ordered for their routine clinical care), so were unable to
assess impact of these variables on test results. In the subset of
subjects whose providers ordered AST testing, elevated AST levels
did not appear to impact the accuracy of the paper-based ALT
test, supporting our prior findings that AST did not interfere with
the ALT test [3]. Third, we note that the lower limit of detection
(LLOD) of the paper-based test (calculated using scanned images
of results obtained using spiked artificial plasma buffer, [3]) is
53 U/L, whereas the LLOD of the automated test is 1 U/L. We
did allow the nurses to call visual results below this formally
calculated LLOD, given that it may be possible to visually
discriminate color changes in this lower range ([3], Fig. 1C).
However, based on this formal LLOD, it would not reliably be
possible to distinguish between completely normal (,40 U/L) and
mildly elevated ALT (e.g. 53 U/L) with the paper-based test as
currently designed. Finally, we note the issue of disagreement
between readers (both those reading together in real time, and
those reading scanned images) in visual interpretation of the
presence or absence of hemolysis in the negative control zone,
which in turn impacts interpretation of device validity. While the
frequency of visibly detectable hemolysis will be addressed by
material quality control, the questions regarding potential
variability in the detection and interpretation of hemolysis remain
and will require additional attention in future field studies.
The clinical diagnostic application chosen for initial demon-
stration of this paper-based microfluidic platform has global
relevance. Hepatotoxicity is a major adverse event associated with
both HIV and TB therapy, and monitoring for DILI is critically
important in the care of these patients. Hepatotoxicity rates
associated with nevirapine-based HIV therapy (widely used in the
developing world, including our study site) can exceed 13%,
depending on treatment course and underlying risk factors
[2,23,24]. The overall incidence of clinically relevant hepatotox-
icity on TB therapy (typically due to isoniazid, rifampin, and/or
pyrazinamide) ranges from 2 to 33%, and risk may be increased by
multiple factors, including hepatitis (B and/or C), alcohol use, and
increasing age [1,25]. Simultaneous treatment for both TB and
HIV can generate additive risk of hepatotoxicity [26,27].
Worldwide, hundreds of other commonly-used drugs have been
Figure 3. Analysis of inter-reader agreement. Visual ALT results recorded by Nurse 1 (ALTN1) were plotted against visual ALT results recorded
by Nurse 2 (ALTN2) for each device to evaluate inter-reader agreement. The black diagonal line corresponds to the line of equality; the green
diagonal lines correspond to +/240 U/L from the line of equality; and the blue boxes represent ALT bins within which values for both readers are
within the same range: ,3x ULN (0–119 U/L), 3 to 5x ULN (120–200 U/L), or .5x ULN (.200 U/L). (ALT=alanine aminotransferase. ULN=upper limit
of normal).
doi:10.1371/journal.pone.0075616.g003
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understanding of DILI pathophysiology and susceptibility contin-
ues [28–30]. In practice, however, it remains difficult to predict
which patients on treatment will actually develop hepatotoxicity
[31], and thus it is essential to actively monitor at-risk patients to
detect DILI.
There are two FDA-approved devices that could potentially be
used for rapid POC testing, Roche ReflotronH Plus (Roche
Diagnostics, Indianapolis, IN) and Cholestech LDXH (Alere, San
Diego, CA), but both are currently off the market in the United
States. Moreover, both are relatively expensive (US$3,000–6,000
for the reader and approximately US$4 per test) and rely on
complex electronics and electricity/battery. While manufacturing
costs for this device are difficult to calculate accurately a priori,
given dependence on several key variables (including location of
manufacturing), DFA anticipates that the device can ultimately be
produced at a cost of less than US$0.10 per test.
An important question to consider as the device is further
optimized for ultimate clinical use is which ALT bin cutoffs would
have the highest utility worldwide given existing country- and
disease-specific clinical management guidelines. Thus far, this test
has been optimized for detection of ALT values .3x and .5x
ULN, given that US TB treatment guidelines [1] emphasize these
cutoffs (in concert with symptoms of hepatotoxicity) for making
management decisions. HIV treatment guidelines in the United
States [2] do not recommend strict ALT (or AST) cutoffs for
clinical management of DILI, but do note that some experts
recommend discontinuing drug treatment when the ALT level
rises to more than 5–10x ULN. The World Health Organization
(WHO) guidelines for HIV treatment [32] use a grading scale for
ALT (and AST) that is identical to the AIDS Clinical Trial Group
(ACTG) adverse event scale [33], with cutoffs at 2.5x, 5x, and 10x
ULN. Minor ALT elevations (defined as less than 5x ULN) can be
managed with observation, and treatment can be continued.
Elevations above 5x ULN, however, prompt discontinuation of
ART. Many developing countries, including Vietnam, South
Africa, and India, have adopted the WHO grading scale for liver
function monitoring in their national HIV treatment guidelines
[22,34,35]. While we hope that optimized visual resolution in the
3–5x ULN range will allow device utility across these varied
guidelines, we are also evaluating a possible ‘‘triage’’ use scenario,
in which paper-based test values above a pre-specified threshold
would prompt automated quantitative testing (by venipuncture).
Performance of the device at various bin cutoffs will continue to be
closely monitored in future field studies.
An additional question is whether the final version of the device
should include only an ALT test, or both AST and ALT tests as in
the prototype tested previously [3]. While most clinicians in the
United States tend to order both ALT and AST measurements,
US guidelines for monitoring for DILI during treatment of TB [1]
focus recommendations on ALT levels, while also noting that AST
can sometimes provide adjunctive information (e.g., alcohol-
related transaminitis); WHO guidelines [36] mention only ALT.
Many international HIV treatment guidelines recommend only
ALT for routine monitoring for DILI in patients on ART. The
Southern African HIV Clinicians Society explicitly cites cost
considerations in their recommendation to use only ALT
measurement for DILI monitoring [34]. The WHO and Vietnam
national HIV treatment guidelines similarly recommend only ALT
monitoring (but without giving any underlying rationale) [22,32].
Because this paper-based microfluidic transaminase test is the
first device of its class to come this far down the pathway towards
clinical use, there are no clear precedents for performance
standards–each aspect of its design and performance is effectively
being evaluated for the first time. Even the question ‘‘how accurate
must this device be in order to be clinically useful?’’ does not have
a simple answer, and we anticipate that this discussion will play a
large role in the regulatory approval process for this device and
other similar devices that follow. Ideally, this device would simply
be just as accurate as automated testing performed on blood
obtained by venipuncture. However, it can be argued that it is
unreasonable to expect the performance of a paper-based test to
exactly match that of an automated test platform. The benefits of
extremely low cost, simplicity, and POC use may ultimately allow
a slightly less accurate paper-based test to have higher overall
clinical impact than a more accurate but expensive and technically
complicated test not available at the POC.
In conclusion, our study provides significant momentum to the
rapidly expanding field of paper-based microfluidics and advances
us towards the goal of providing universal access to POC screening
for DILI. We anticipate that this device, once development is
complete, will make extremely inexpensive and minimally invasive
transaminase testing available at POC for all who need it,
providing distinct advantages over current automated methods
using venipuncture. Given that aversion to venipuncture can be a
barrier to optimal care [37], this fingerstick test could conceivably
also improve treatment adherence. Finally, this work opens the
door to development of similar paper-based assays for other
clinically important analytes.
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